Autologous Ccr4 Car T Cells
Neoplasm Of Mature T-Cells Or NK-Cells
Explore 5 assets in Neoplasm Of Mature T-Cells Or NK-Cells →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07055477CT.gov A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm Of Mature T-Cells Or NK-Cells
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Ccr4 Car T Cells (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Copanlisib | Chonnam National University Hospital | P1/2 | CCC |
| Bortezomib | Swiss Cancer Institute | P1 | CC |
| Nelfinavir | Swiss Cancer Institute | P1 | CC |
| Cyclophosphamide | National Cancer Institute (NCI) | P1 | CC |
| Ruxolitinib | Memorial Sloan Kettering Cancer Center | P1 | CC |
| Duvelisib | Memorial Sloan Kettering Cancer Center | P1 | CC |
| Fludarabine | National Cancer Institute (NCI) | P1 | CC |
Other indications for Autologous Ccr4 Car T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatosplenic T-Cell Lymphoma | — | P1 | CC · 43 |
| Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | — | P1 | CC · 43 |
| Enteropathy-Associated T-Cell Lymphoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Ccr4 Car T Cells in Neoplasm Of Mature T-Cells Or NK-Cells. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-ccr4-car-t-cells-neoplasm-of-mature-t-cells-or-nk-cells
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →